HCA Healthcare, Inc. Q3 2026 Earnings Recap

HCA shares fell 3.3% after earnings, with investors likely focused on management’s preliminary view that 2027 earnings will be generally consistent with 2026—not a return to growth—amid persistent payer-mix pressure and $550 million to $650 million less in Medicaid supplemental payment net benefits. Third-quarter volumes improved, but exchange-related shifts to uninsured patients weighed on EBITDA.

Key Takeaways

• Same-facility adjusted admissions grew 3%; equivalent admissions rose 3% and ER visits increased 5.1%.
• Exchange equivalent admissions fell approximately 19% year over year, while uninsured patients rose to 10.5% of equivalent admissions from 8.5%; the payer-mix shift reduced quarterly adjusted EBITDA by an estimated $400 million.
• Insured revenue per adjusted admission, excluding supplemental payments, increased at a higher rate than in the first half; a $50 million incremental net benefit from Medicaid supplemental payment programs also supported the quarter.
• Adjusted diluted EPS increased almost 4%, and management said quarterly financial performance slightly exceeded its expectations.
• For 2027, management expects 2%–3% volume growth and favorable cost performance, but anticipates $550 million–$650 million less in Medicaid supplemental payment net benefits and earnings generally consistent with 2026.